Filtered By:
Condition: Heart Attack
Infectious Disease: COVID-19
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 684 results found since Jan 2013.
Readmission Risk after COVID-19 Hospitalization: A Moderation Analysis by Vital Signs
CONCLUSIONS: Comorbid conditions, including pulmonary and cardiovascular disease, are associated with readmission risk after COVID-19 hospitalization. The normalization of vital signs within 24 hours of discharge during COVID-19 hospitalization may be an indicator of readiness for discharge and may mitigate some readmission risk conferred by comorbid conditions.PMID:36318952 | PMC:PMC9612414 | DOI:10.14423/SMJ.0000000000001472
Source: Southern Medical Journal - November 1, 2022 Category: General Medicine Authors: Arkadiy Finn Joshua R Tanzer Atin Jindal Vijairam Selvaraj Bradley Collins Kwame Dapaah-Afriyie Source Type: research
Endogenous reparative pluripotent Muse cells with a unique immune privilege system: Hint at a new strategy for controlling acute and chronic inflammation
Multilineage-differentiating stress enduring (Muse) cells, non-tumorigenic endogenous pluripotent stem cells, reside in the bone marrow (BM), peripheral blood, and connective tissue as pluripotent surface marker SSEA-3(+) cells. They express other pluripotent markers, including Nanog, Oct3/4, and Sox2 at moderate levels, differentiate into triploblastic lineages, self-renew at a single cell level, and exhibit anti-inflammatory effects. Cultured mesenchymal stromal cells (MSCs) and fibroblasts contain several percent of SSEA-3(+)-Muse cells. Circulating Muse cells, either endogenous or administered exogenously, selectively ...
Source: Frontiers in Pharmacology - October 19, 2022 Category: Drugs & Pharmacology Source Type: research
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research
The impact of first wave of the SARS-CoV-2 2019 pandemic in Poland on characteristics and outcomes of patients hospitalized due to stable coronary artery disease
CONCLUSIONS: The SARS-CoV-2 2019 pandemic affected the characteristics and hospitalization course of stable angina patients hospitalized following the first wave. The hospitalization outcome was similar in the analyzed time intervals. The higher prevalence of comorbidities raises concern regarding upcoming years.PMID:36200545 | DOI:10.5603/CJ.a2022.0094
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Justyna Jankowska-Sanetra Krzysztof Sanetra Marta Konopko Monika Kutowicz Magdalena Synak Krzysztof Milewski Pawe ł Kaźmierczak Łukasz Kołtowski Piotr P Buszman Source Type: research
